A list of changes in the level of risk of products reviewed in e-lactancia during the last 3 months is shown. Tap the name of a product to access to its full information.

Probiotics

Level of risk reviewed on 29/11/2019

Increased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Very Low Risk, is now set to Low Risk.

Sulfanilamide

Level of risk reviewed on 29/11/2019

Increased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Very Low Risk, is now set to Low Risk.

Dipyridamole

Level of risk reviewed on 29/11/2019

Increased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Very Low Risk, is now set to Low Risk.

Armodafinil

Level of risk reviewed on 27/11/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Rivaroxaban

Level of risk reviewed on 25/11/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.

Rituximab

Level of risk reviewed on 19/11/2019

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was Low Risk, is now set to Very Low Risk.